Nicola Thompson
Directeur Général chez Amphista Therapeutics Ltd.
Profil
Nicola Thompson is currently the Chief Executive Officer and Director at Amphista Therapeutics Ltd.
Prior to this, she worked as the Chief Executive Officer at Virion Biotherapeutics Ltd.
She also held positions as a Principal at GSK Plc and GlaxoWellcome.
Additionally, she worked as the Head of Cell Biology at Ipsen Bioinnovation Ltd.
Postes actifs de Nicola Thompson
| Sociétés | Poste | Début |
|---|---|---|
Amphista Therapeutics Ltd.
 Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Directeur Général | - |
Anciens postes connus de Nicola Thompson
| Sociétés | Poste | Fin |
|---|---|---|
Virion Biotherapeutics Ltd.
 Virion Biotherapeutics Ltd. BiotechnologyHealth Technology Virion Biotherapeutics Ltd. operates as a biotechnology company that develops novel therapeutics for respiratory viral infections. The firm focuses on prevention and treatment of influenza and respiratory syncytial virus. The company was founded by Nigel Dimmock and Andrew Easton in 2017 and is headquartered in Coventry, the United Kingdom. | Directeur Général | - |
| GlaxoWellcome /Pharmocology Unit/ | Corporate Officer/Principal | - |
| GSK PLC | Corporate Officer/Principal | - |
Ipsen Bioinnovation Ltd.
 Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
Ipsen Bioinnovation Ltd.
Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
| GlaxoWellcome /Pharmocology Unit/ | Commercial Services |
Virion Biotherapeutics Ltd.
Virion Biotherapeutics Ltd. BiotechnologyHealth Technology Virion Biotherapeutics Ltd. operates as a biotechnology company that develops novel therapeutics for respiratory viral infections. The firm focuses on prevention and treatment of influenza and respiratory syncytial virus. The company was founded by Nigel Dimmock and Andrew Easton in 2017 and is headquartered in Coventry, the United Kingdom. | Health Technology |
Amphista Therapeutics Ltd.
Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Health Technology |
